CyberKnife® VSI System Expands Treatment Applications and Significantly Reduces Treatment Times
CyberKnife® VSI System Expands Treatment Applications and Significantly Reduces Treatment Times
Accuray Incorporated , a global leader in the field of radiosurgery, announced today feedback from Creekside Cancer Care on their use of the CyberKnife VSI System. Â Creekside Cancer Care was the first facility in the world to install and begin treating patients with the CyberKnife VSI System. Â Patient treatments began in June 2010 and clinicians at Creekside Cancer Care quickly reported that …
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Doctors Tags: Applications, CyberKnife®, expands, Reduces, significantly, system, Times, Treatment
Power3 Medical Announces Filing of Two Provisional Patent Applications with the USPTO
Power3 Medical Announces Filing of Two Provisional Patent Applications with the USPTO
HOUSTON—-Power3 Medical Products, Inc. announced today that it has filed two provisional patent applications with the United States Patent and Trademark Office – one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Treatment Options Tags: Announces, Applications, Filing, Medical, Patent, Power3, Provisional, USPTO
Eisai Submits Simultaneous Regulatory Applications for Approval of Eribulin Mesylate in Japan, U.S. and EU
Eisai Submits Simultaneous Regulatory Applications for Approval of Eribulin Mesylate in Japan, U.S. and EU
Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union .
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Research Tags: Applications, Approval, Eisai, Eribulin, Japan, Mesylate, Regulatory, Simultaneous, Submits, U.S.